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RESEARCH LETTERS
Chloroquine-resistant Plasmodium
malariae in south Sumatra,
Indonesia
Jason D Maguire, Iwa W Sumawinata, Sofyan Masbar, 
Budhi Laksana, Purnomo Prodjodipuro, Ika Susanti, 
Priyanto Sismadi, Nurlis Mahmud, Michael J Bangs, 
J Kevin Baird
Oral chloroquine is the treatment of choice for uncomplicated
Plasmodium malariae infections worldwide. We did a
prospective 28-day in-vivo assessment of the efficacy of
chloroquine for treatment of P malariae on Legundi Island in
Lampung Bay, Sumatra, Indonesia. Of 28 patients, one had
recurrent parasitaemia on day 28, and two had persistent
parasitaemia to day 8. Whole-blood chloroquine and
desethylchloroquine concentrations were at ordinarily
effective levels (100 g/L) on day 8 in both cases of
persistent parasitaemia. These findings suggest that clinical
resistance to chloroquine by P malariae occurs in the
Indonesian archipelago of southeast Asia.
Lancet 2002; 360: 58–60
Plasmodium malariae causes quartan malaria—an important
re-emerging parasitic disease around the globe. Although
well described in eastern Indonesia and common in Java
and Sumatra during the early 20th century, we have found
no recent record of P malariae in the western Indonesian
archipelago. Oral chloroquine remains the treatment of
choice for uncomplicated quartan malaria, and although
chloroquine therapy for Plasmodium falciparum and
Plasmodium vivax infections in Indonesia often fails,
P malariae is presumed sensitive to chloroquine, and
resistance has not been documented.
In August, 2000, we identified a focus of P malariae on
the island of Legundi in Lampung Bay near the
southernmost tip of Sumatra at the Sunda Strait. Since
chloroquine use is heavy in this area, we aimed to find 
out whether chloroquine resistance could develop in 
P malariae. Infected individuals were identified by a cross-
sectional prevalence survey for malaria, and were enrolled
in a 28-day in-vivo test of resistance to chloroquine.
Patients were treated with the standard chloroquine
regimen, in accordance with a protocol approved by the
United States Naval Medical Research Unit Institutional
controls 6·7 years, SD 2·2). If more than one control was a
possible match, we selected the control with the closest
body-mass index. 908 individuals met baseline criteria and
had suitable baseline samples (stored at –70°C) for this
study. 101 (11%) of these 908 participants developed
diabetes, of whom 70 (70%) were matched to appropriate
controls. To avoid bias, we selected controls independently
of whether they later developed disease, and controls could
be selected more than once. We included baseline
measurements for 127 people, with nine individuals
selected twice and two selected three times. Adiponectin
was measured by ELISA from the 2-h sample of the
OGTT.3 We compared baseline characteristics between
patients and controls with the paired t test. The relation of
adiponectin to body-mass index and biochemical measures
was assessed by Spearman correlation. The relation of
baseline adiponectin to later risk of type 2 diabetes was
modelled by conditional logistic regression with SAS
version 8 to estimate the incidence rate ratio.
At baseline, patients did not differ from controls in
plasma glucose (fasting or 2 h), fasting insulin, body-mass
index, waist circumference, or age (table). By contrast, the
concentration of adiponectin was significantly lower in
patients than in controls (table). In cross-sectional analysis,
adiponectin was negatively correlated with fasting glucose
(r=–0·18; p=0·04), 2-h glucose (r=–0·17; p=0·05), body-
mass index (r=–0·18; p=0·04), and fasting insulin
(r=–0·26; p=0·003).
In univariate analysis, higher concentrations of
adiponectin protected against later development of type 2
diabetes (incidence rate ratio 0·63 [95% CI 0·43–0·92],
p=0·02). Higher adiponectin remained protective against
type 2 diabetes after inclusion of age, fasting glucose, 2-h
glucose, fasting insulin, and waist circumference as
covariates (0·59 [0·38–0·91], p=0·02; figure).
In cross-sectional studies, adiponectin has been
associated with obesity, type 2 diabetes, and insulin
resistance.3 Furthermore, administration of adiponectin
improves sensitivity to insulin in animal models of insulin
resistance and type 2 diabetes,5 and insulin sensitising
agents increase adiponectin concentations in human
beings.4 Thus, our findings lend support to the hypothesis
that adiponectin has a key role in the connection between
obesity, insulin resistance, and subsequent development of
type 2 diabetes.
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Review Board and the ethical review committee of the host
country. All patients provided informed consent. Patients
received directly observed doses of chloroquine
diphosphate (Resochin, P T Bayer Indonesia, Jakarta): 10 mg
base/kg on day 0, 10 mg base/kg on day 1, and 5 mg
base/kg on day 2, and were followed up for 28 days.
Malaria smears were prepared on days 0, 1, 2, 3, 4, 7,
11, 14, 18, 21, 28, or any day a patient complained of
illness. Blood-blot specimens were obtained for
measurement of whole-blood chloroquine concentrations
by high-performance liquid chromatography (Model 2700,
Bio-Rad, Richmond, CA, USA) on day 0 (pretreatment),
day 2, day 28, or the day of recurrent parasitaemia. Blood-
blot specimens were also obtained for plasmodial DNA
analysis on days 0, 7, 14, 21, 28, or the day of recurrent
parasitaemia. Patients with persistent or recurrent
parasitaemia during follow-up were treated with
pyrimethamine-sulfadoxine according to Indonesian
Ministry of Health guidelines. Studies done elsewhere show
that, after standard chloroquine therapy, P malariae
parasitaemia clears within 24–72 h and does not recur.1,2
We therefore considered P malariae parasitaemia persisting
beyond 72 h as evidence of an inadequate therapeutic
response consistent with chloroquine resistance.
Active screening of 41% (752/1819) of the population
revealed an overall 17% (127/752) prevalence of
parasitaemia by plasmodia (31·5% 
P falciparum, 30% P vivax, 37% 
P malariae, 1·5% both P falciparum and
P vivax). At the two primary villages of
Selesung and Keramat, prevalence was
15% (59/408) and 23% (56/247),
respectively. P malariae was the most
common species at both locations,
accounting for 41% (24/59) in Selesung
and 39% (22/56) of positive smears in
Keramat. Spleen rates and average
enlarged spleen (AES) indices among
children (2–9 years) were 68% (59/87;
AES 1·8) in Selesung and 81% (43/53;
AES 2·7) in Keramat.
Among 47 patients with P malariae
infection in the prevalence survey, we
enrolled 28 in the test of resistance to
chloroquine. 15 were male and 13 were
female, and ages ranged from 6 to 65
years (mean 13). Four patients had
mixed P malariae and P vivax infections.
One declined further participation after
day 2, which left 27 individuals who
successfully completed the test. The
mean asexual parasite count was 220/L
(range 40–1120) at baseline. Only one
patient had detectable P malariae
gametocytes. The blood of 18 in-
dividuals had evidence of chloroquine
and its major metabolite desethyl-
chloroquine before treatment (mean
concentration 142·5 g/L [SD 116·5]),
which suggested that island residents
practised routine self-administration of
chloroquine.
All but two of the 28 enrolled patients
cleared P malariae parasitaemia after
treatment. The mean time to asexual-
stage parasite clearance in 24 of 26
individuals who initially cleared
parasitaemia, irrespective of eventual
outcome, was 2 days (range 1–4). The
times to clearance could not be determined in the other two
patients. In both cases, parasitaemia was still present on
day 4, but the patients did not undergo another malaria
smear until day 7 in 1 case and day 13 in the other, at
which time malaria smears were negative for parasites.
18 of the 27 individuals who completed the test
remained parasite-free on day 28. During follow-up, six
patients developed asexual-stage parasitaemia with a
species other than P malariae: three with P falciparum on
day 18, one with P vivax on day 21, and two with P vivax
on day 28. These cases represented intercurrent infections
with a different species or possibly relapse in cases of 
P vivax infection.
Of the three remaining patients, two had persistent
P malariae parasitaemia to day 8, and one had recurrent
parasitaemia on day 28. The 28-day cumulative incidence
of therapeutic failure was 12% by life-table (actuarial)
analysis. Thick-smear asexual parasite counts (per L) for
the two patients with persistent parasitaemia on days 0, 1,
2, 3, 4, 7, and 8 were 520, 120, not done, not done, 80, 80,
40; and 520, 240, 40, 80, 80, 80, 80, respectively. In the
same two individuals, day 2 chloroquine and
desethylchloroquine concentrations were 205 g/L and 
680 g/L, respectively. Just before rescue therapy with
pyrimethamine-sulfadoxine on day 8, their chloroquine and
desethylchloroquine concentrations were 100 g/L and 
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Figure 1: Giemsa-stained peripheral blood in patients with Plasmodium malariae
infection
A: Day-7 sample from patient with persistent P malariae parasitaemia. On day 8, this patient’s
whole-blood chloroquine and desethylchloroquine concentration was 170 g/L and was positive
for P malariae and P falciparum. Note characteristic course, scattered, golden pigment and
vacuolated late trophozoite form in normal-sized red blood cell. B: Day-8 sample from patient
whose whole-blood chloroquine and desethylchloroquine concentration was 100 g/L and was
positive for P malariae and negative for P falciparum. Note ring stage in normal-sized red blood
cell with prominent Ziemann’s stippling.
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single dose of 600 mg chloroquine base rather than a
standard 3-day regimen. Those parasite clearance times
cannot therefore be compared with those in naturally
infected patients treated with the standard 3-day course of
chloroquine. The presence of early ring-form parasites as
late as day 8 (figure 1) also suggests ongoing schizogony.
The persistence of healthy asexual-stage parasitaemia to
day 8 after adequate chloroquine absorption and in the
presence of ordinarily effective chloroquine and
desethylchloroquine concentrations5 is highly suggestive of
resistance to chloroquine by P malariae.
Health-care providers could encounter patients with
uncomplicated P malariae infection that proves
unresponsive to the recommended chloroquine regimen.
Further assessment of chloroquine-resistant P malariae at
other locations around the world is needed, particularly in
areas where indiscriminate chloroquine use is common and
could lead to inadequate dosing and selection for resistant
organisms.
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170 g/L. The patient with recurrent P malariae
parasitaemia on day 28 cleared parasitaemia 1 day after
initiation of therapy and had a chloroquine and
desethylchloroquine concentration of 450 g/L on day 2,
which we deemed consistent with adequate absorption of
drug. The chloroquine and desethylchloroquine
concentration on the day of recurrence was 35 g/L.
Diagnoses were established by standard light microscopy
and PCR. The microscopic diagnosis of P malariae was
based on the presence of characteristic pigmented band
forms and scattered, course pigment granules in
prominently vacuolated late trophozoites in normal-sized
red blood cells (figure 1). Diagnoses of recurrent or
persistent P malariae infection were confirmed by species-
specific single-stranded ribosomal RNA PCR methods.3 In
all three cases of therapeutic failure, blood-blot specimens
obtained on day 0 and the day of rescue therapy were
positive for P malariae by PCR (figure 2). Neither P vivax
nor P ovale were detected in these specimens. One of the
patients with persistent P malariae parasitaemia on day 8
was also PCR-positive for P falciparum on day 0 and day 8.
We believe that this individual might have had a mixed
infection with subpatent P falciparum parasitaemia.
P malariae can suppress parasitaemia of subsequent 
P falciparum superinfections.4
The case of recurrent P malariae parasitaemia on day 28
could represent either new infection or late recrudescence
of a chloroquine-resistant strain, but the two cases of 
P malariae persisting for 8 days after directly observed
chloroquine therapy with adequate absorption constitute
evidence of resistance. The time to parasite clearance seen
in this study and others1,2 supports our view that these two
cases represent treatment failures due to inadequate
therapeutic response by the parasite, rather than delayed
clearance. Although P malariae has a longer cycle of
schizogony than other human plasmodia, we have seen no
evidence to suggest that chloroquine-sensitive P malariae
survives beyond 72 h after the patient starts standard
chloroquine treatment. Figure 1 shows that these patients
still carried developing late trophozoites 7 days after
initiation of chloroquine therapy. In previous reports of
natural infection,2 time to parasite clearance did not 
exceed 2 days. Collins and colleagues1 reported
13 chloroquine-treated experimental P malariae infections
with parasite clearance times ranging from 1 to 7 days.
However, these were experimental infections, many of
which were manipulated by low-dose quinine sulphate for
several months before definitive treatment with
chloroquine, and in most cases, patients received only a
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Figure 2: Electrophoresis after Plasmodium-malariae-specific
PCR amplification
Lanes 1 and 15: bp ladder; lane 2: patient LG004 day 0; lane 3:
patient LG004 day 28; lane 4: patient LG033 day 0; lane 5: patient
LG033 day 8; lane 6: patient LG046 day 0; lane 7: patient LG046 day
8; lane 8: P malariae positive control; lane 9: P falciparum control; lane
10: P vivax control; lane 11: P ovale control; lanes 12, 13, and 14:
negative controls.
